Decreased expression of MIR-204 in plasma is associated with a poor prognosis in patients with non-small cell lung cancer

International Journal of Molecular Medicine

Volumn 36, Issue 6, 2015, Pages 1720-1726

  Guo, Weigang ^a   Zhang, Yongxing ^a   Zhang, Yi ^a   Shi, Yu ^a   Xi, Junjie ^a   Fan, Hong ^a   Xu, Songtao ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Diagnosis; MIR 204; Non small cell lung cancer; Plasma; Prognosis

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; MICRORNA; MICRORNA 106A; MICRORNA 124; MICRORNA 146; MICRORNA 204; UNCLASSIFIED DRUG; MIRN204 MICRORNA, HUMAN; TUMOR MARKER;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS; BLOOD; CARCINOMA, NON-SMALL-CELL LUNG; GENE EXPRESSION REGULATION; GENETICS; LUNG; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; STATISTICS AND NUMERICAL DATA;

BIOMARKERS, TUMOR; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG; LUNG NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; ROC CURVE;

EID: 84945326180     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2015.2388     Document Type: Article

References (38)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 59: 225-249, 2009.
2. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63: 11-30, 2013.
3. Wu YL and Zhou Q: Clinical trials and biomarker research on lung cancer in China. Expert Opin Ther Targets 16 (Suppl 1): S45-S50, 2012.
4. Dykxhoorn DM: MicroRNAs and metastasis: little RNAs go a long way. Cancer Res 70: 6401-6406, 2010.
5. Garzon R, Fabbri M, Cimmino A, Calin GA and Croce CM: MicroRNA expression and function in cancer. Trends Mol Med 12: 580-587, 2006.
6. Zhang B, Pan X, Cobb GP and Anderson TA: microRNAs as oncogenes and tumor suppressors. Dev Biol 302: 1-12, 2007.
7. Li W, Wang Y, Zhang Q, Tang L, Liu X, Dai Y, Xiao L, Huang S, Chen L, Guo Z, Lu J and Yuan K: MicroRNA-486 as a biomarker for early diagnosis and recurrence of non-small cell lung cancer. PLoS One 10: e0134220, 2015.
8. Mavridis K, Gueugnon F, Petit-Courty A, Courty Y, Barascu A, Guyetant S and Scorilas A: The oncomiR miR-197 is a novel prognostic indicator for non-small cell lung cancer patients. Br J Cancer 112: 1527-1535, 2015.
9. Tejero R, Navarro A, Campayo M, Viñolas N, Marrades RM, Cordeiro A, Ruíz-Martínez M, Santasusagna S, Molins L, Ramirez J and Monzó M: miR-141 and miR-200c as markers of overall survival in early stage non-small cell lung cancer adenocarcinoma. PLoS One 9: e101899, 2014.
10. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, et al: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105: 10513-10518, 2008.
11. Patnaik SK, Mallick R and Yendamuri S: Detection of microRNAs in dried serum blots. Anal Biochem 407: 147-149, 2010.
12. Yang X, Zeng Z, Hou Y, Yuan T, Gao C, Jia W, Yi X and Liu M: MicroRNA-92a as a potential biomarker in diagnosis of colorectal cancer: a systematic review and meta-Analysis. PLoS One 9: e88745, 2014.
13. Shen J, Hruby GW, McKiernan JM, Gurvich I, Lipsky MJ, Benson MC and Santella RM: Dysregulation of circulating microRNAs and prediction of aggressive prostate cancer. Prostate 72: 1469-1477, 2012.
14. Ng EK, Li R, Shin VY, Jin HC, Leung CP, Ma ES, Pang R, Chua D, Chu KM, Law WL, et al: Circulating microRNAs as specific biomarkers for breast cancer detection. PLoS One 8: e53141, 2013.
15. Gorur A, Balci Fidanci S, Dogruer Unal N, Ayaz L, Akbayir S, Yildirim Yaroglu H, Dirlik M, Serin MS and Tamer L: Determination of plasma microRNA for early detection of gastric cancer. Mol Biol Rep 40: 2091-2096, 2013.
16. Zhang B, Yin Y, Hu Y, Zhang J, Bian Z, Song M, Hua D and Huang Z: MicroRNA-204-5p inhibits gastric cancer cell proliferation by downregulating USP47 and RAB22A. Med Oncol 32: 331, 2015.
17. Li W, Jin X, Zhang Q, Zhang G, Deng X and Ma L: Decreased expression of miR-204 is associated with poor prognosis in patients with breast cancer. Int J Clin Exp Pathol 7: 3287-3292, 2014.
18. Munari E, Marchionni L, Chitre A, Hayashi M, Martignoni G, Brunelli M, Gobbo S, Argani P, Allaf M, Hoque MO and Netto GJ: Clear cell papillary renal cell carcinoma: micro-RNA expression profiling and comparison with clear cell renal cell carcinoma and papillary renal cell carcinoma. Hum Pathol 45: 1130-1138, 2014.
19. Shi L, Zhang B, Sun X, Lu S, Liu Z, Liu Y, Li H, Wang L, Wang X and Zhao C: MiR-204 inhibits human NSCLC metastasis through suppression of NUAK1. Br J Cancer 111: 2316-2327, 2014.
20. Imam JS, Plyler JR, Bansal H, Prajapati S, Bansal S, Rebeles J, Chen HI, Chang YF, Panneerdoss S, Zoghi B, et al: Genomic loss of tumor suppressor miRNA-204 promotes cancer cell migration and invasion by activating AKT/mTOR/Rac1 signaling and actin reorganization. PLoS One 7: e52397, 2012.
21. Yin Y, Zhang B, Wang W, Fei B, Quan C, Zhang J, Song M, Bian Z, Wang Q, Ni S, et al: miR-204-5p inhibits proliferation and invasion and enhances chemotherapeutic sensitivity of colorectal cancer cells by downregulating RAB22A. Clin Cancer Res 20: 6187-6199, 2014.
22. Wu X, Zeng Y, Wu S, Zhong J, Wang Y and Xu J: MiR-204, down-regulated in retinoblastoma, regulates proliferation and invasion of human retinoblastoma cells by targeting CyclinD2 and MMP-9. FEBS Lett 589: 645-650, 2015.
23. Li G, Luna C, Qiu J, Epstein DL and Gonzalez P: Role of miR-204 in the regulation of apoptosis, endoplasmic reticulum stress response, and inflammation in human trabecular meshwork cells. Invest Ophthalmol Vis Sci 52: 2999-3007, 2011.
24. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-Dime quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408, 2001.
25. Niklinski J, Furman M, Laudanski J and Kozlowski M: Prognostic value of pretreatment CEA, SCC-Ag and CA 19-9 levels in sera of patients with non-small cell lung cancer. Eur J Cancer Prev 1: 401-406, 1992.
26. Ruopp MD, Perkins NJ, Whitcomb BW and Schisterman EF: Youden Index and optimal cut-point estimated from observations affected by a lower limit of detection. Biom J 50: 419-430, 2008.
27. Schwarzenbach H, Nishida N, Calin GA and Pantel K: Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol 11: 145-156, 2014.
28. Kang K, Peng X, Luo J and Gou D: Identification of circulating miRNA biomarkers based on global quantitative real-Dime PCR profiling. J Anim Sci Biotechnol 3: 4, 2012.
29. Wang J, Zhang KY, Liu SM and Sen S: Tumor-Associated circulating microRNAs as biomarkers of cancer. Molecules 19: 1912-1938, 2014.
30. Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK and Calin GA: MicroRNAs in body fluids-Dhe mix of hormones and biomarkers. Nat Rev Clin Oncol 8: 467-477, 2011.
31. Jia W, Wu Y, Zhang Q, Gao G, Zhang C and Xiang Y: Identification of four serum microRNAs from a genome-wide serum microRNA expression profile as potential non-invasive biomarkers for endometrioid endometrial cancer. Oncol Lett 6: 261-267, 2013.
32. Wang Y, Li W, Zang X, Chen N, Liu T, Tsonis PA and Huang Y: MicroRNA-204-5p regulates epithelial-Do-mesenchymal transition during human posterior capsule opacification by targeting SMAD4. Invest Ophthalmol Vis Sci 54: 323-332, 2013.
33. Zhou X, Li L, Su J and Zhang G: Decreased miR-204 in H. pylori-Associated gastric cancer promotes cancer cell proliferation and invasion by targeting SOX4. PLoS One 9: e101457, 2014.
34. Xia Y, Zhu Y, Ma T, Pan C, Wang J, He Z, Li Z, Qi X and Chen Y: miR-204 functions as a tumor suppressor by regulating SIX1 in NSCLC. FEBS Lett 588: 3703-3712, 2014.
35. Ma L, Deng X, Wu M, Zhang G and Huang J: Down-regulation of miRNA-204 by LMP-1 enhances CDC42 activity and facilitates invasion of EBV-Associated nasopharyngeal carcinoma cells. FEBS Lett 588: 1562-1570, 2014.
36. Bao W, Wang HH, Tian FJ, He XY, Qiu MT, Wang JY, Zhang HJ, Wang LH and Wan XP: A TrkB-STAT3-miR-204-5p regulatory circuitry controls proliferation and invasion of endometrial carcinoma cells. Mol Cancer 12: 155, 2013.
37. Ryan J, Tivnan A, Fay J, Bryan K, Meehan M, Creevey L, Lynch J, Bray IM, O'Meara A, Tracey L, et al: MicroRNA-204 increases sensitivity of neuroblastoma cells to cisplatin and is associated with a favourable clinical outcome. Br J Cancer 107: 967-976, 2012.
38. Sacconi A, Biagioni F, Canu V, Mori F, Di Benedetto A, Lorenzon L, Ercolani C, Di Agostino S, Cambria AM, Germoni S, et al: miR-204 targets Bcl-2 expression and enhances responsiveness of gastric cancer. Cell Death Dis 3: e423, 2012.